Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials